NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
METOZOLV ODT (metoclopramide hydrochloride) by Bausch Health is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. First approved in 2009.
Drug data last refreshed 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
METOZOLV ODT is an orally disintegrating tablet formulation of metoclopramide hydrochloride, a dopamine antagonist that enhances upper gastrointestinal motility and prevents nausea and vomiting. It works by sensitizing GI tissues to acetylcholine and blocking dopamine receptors in the chemoreceptor trigger zone, accelerating gastric emptying and increasing lower esophageal sphincter pressure. This product treats nausea and vomiting across multiple clinical contexts.
LOE Approaching
LOE-approaching lifecycle signals declining commercial investment and potential team restructuring; brand roles may transition toward maintenance or portfolio optimization.
Mechanism of Action
CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…
Worked on METOZOLV ODT at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.